BR112021011684A2 - Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda - Google Patents

Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda

Info

Publication number
BR112021011684A2
BR112021011684A2 BR112021011684A BR112021011684A BR112021011684A2 BR 112021011684 A2 BR112021011684 A2 BR 112021011684A2 BR 112021011684 A BR112021011684 A BR 112021011684A BR 112021011684 A BR112021011684 A BR 112021011684A BR 112021011684 A2 BR112021011684 A2 BR 112021011684A2
Authority
BR
Brazil
Prior art keywords
bcl
inhibitor
treatment
venetoclax
myeloid leukemia
Prior art date
Application number
BR112021011684A
Other languages
English (en)
Inventor
Adrian Ochsenbein
Carsten Riether
De Haard Hans
Van Rompaey Luc
Nicolas Leupin
Samson Fung
Original Assignee
Argenx Bvba
Univ Of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820582.3A external-priority patent/GB201820582D0/en
Priority claimed from GBGB1911007.1A external-priority patent/GB201911007D0/en
Priority claimed from GBGB1917701.3A external-priority patent/GB201917701D0/en
Application filed by Argenx Bvba, Univ Of Bern filed Critical Argenx Bvba
Publication of BR112021011684A2 publication Critical patent/BR112021011684A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda. a invenção se refere a terapias combinadas, particularmente terapias combinadas para o tratamento de malignidade mieloide. as terapias combinadas são particularmente úteis em métodos para o tratamento de leucemia mieloide aguda (lma). as terapias combinadas incluem um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a cd70 e um inibidor de bcl-2, de preferência venetoclax ou um sal farmaceuticamente aceitável do mesmo.
BR112021011684A 2018-12-18 2019-12-18 Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda BR112021011684A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1820582.3A GB201820582D0 (en) 2018-12-18 2018-12-18 CD70 combination therapy
GBGB1911007.1A GB201911007D0 (en) 2019-08-01 2019-08-01 CD70 combination therapy
GBGB1917701.3A GB201917701D0 (en) 2019-12-04 2019-12-04 CD70 Combination therapy
PCT/EP2019/085982 WO2020127503A1 (en) 2018-12-18 2019-12-18 Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BR112021011684A2 true BR112021011684A2 (pt) 2021-11-30

Family

ID=69104399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011684A BR112021011684A2 (pt) 2018-12-18 2019-12-18 Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda

Country Status (21)

Country Link
US (2) US11712468B2 (pt)
EP (2) EP4218761A1 (pt)
JP (1) JP2022515077A (pt)
KR (1) KR20210106428A (pt)
CN (2) CN115920034A (pt)
AU (1) AU2019409936A1 (pt)
BR (1) BR112021011684A2 (pt)
CA (1) CA3117282A1 (pt)
DK (1) DK3890740T3 (pt)
ES (1) ES2941638T3 (pt)
FI (1) FI3890740T3 (pt)
HU (1) HUE061710T2 (pt)
IL (1) IL284015A (pt)
LT (1) LT3890740T (pt)
MX (1) MX2021007350A (pt)
PL (1) PL3890740T3 (pt)
PT (1) PT3890740T (pt)
SG (1) SG11202105197UA (pt)
TW (1) TW202038958A (pt)
UY (1) UY38511A (pt)
WO (1) WO2020127503A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202038958A (zh) 2018-12-18 2020-11-01 比利時商阿根思公司 Ｃｄ７０組合治療
BR112021025375A2 (pt) * 2019-06-20 2022-02-01 Celgene Corp Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para tratamento de leucemia ou síndrome mielodisplástica
TW202138388A (zh) * 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
MX2023002318A (es) * 2020-08-29 2023-05-19 argenx BV Metodo de tratamiento de pacientes con sensibilidad reducida a un inhibidor de bcl-2.
AU2022316138A1 (en) * 2021-07-21 2023-11-30 Emory University Bak activators, pharmaceutical compositions, and uses in treating cancer
TW202319400A (zh) * 2021-09-02 2023-05-16 瑞士商赫孚孟拉羅股份公司 用於治療aml之抗體
WO2023081721A1 (en) * 2021-11-03 2023-05-11 Board Of Regents, The University Of Texas System Methods relating to treatment of acute myeloid leukemia
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
CN114949230A (zh) * 2022-06-13 2022-08-30 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN117771177A (zh) * 2023-08-02 2024-03-29 首都医科大学附属北京儿童医院 维奈克拉自微乳化释药系统及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
NZ533240A (en) 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP5222559B2 (ja) 2004-10-15 2013-06-26 シアトル ジェネティックス， インコーポレイテッド 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用
US20060275844A1 (en) 2005-04-19 2006-12-07 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
WO2007038637A2 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CN101489697B (zh) 2006-07-24 2011-06-01 千田建设股份有限公司 金属线材除锈的方法及其装置
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
EP2217223A2 (en) 2007-11-05 2010-08-18 Novartis AG Methods and compositions for measuring wnt activation and for treating wnt-related cancers
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010019921A2 (en) 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2987487T3 (da) 2009-08-10 2020-12-07 Samumed Llc Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
US20120178111A1 (en) 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
KR101773216B1 (ko) 2009-12-29 2017-08-31 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ27 항체
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
DK2665749T3 (en) 2011-01-19 2016-03-21 Cantargia Ab Anti-il1rap antibodies and their use for the treatment of solid tumors
JP5982409B2 (ja) 2011-03-16 2016-09-07 アルゲン−エックス エヌ．ブイ． Ｃｄ７０に対する抗体
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CA2849318C (en) 2011-09-22 2019-11-12 Amgen Inc. Cd27l antigen binding proteins
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
UA121844C2 (uk) 2012-03-15 2020-08-10 Янссен Байотек, Інк. Людське антитіло до cd27, спосіб його одержання та застосування
WO2013139906A1 (en) 2012-03-21 2013-09-26 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
WO2013177420A2 (en) 2012-05-23 2013-11-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
CA2875372C (en) 2012-06-15 2019-04-09 Curegenix Inc. Compound as wnt signaling inhibitor, composition, and use thereof
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014100772A1 (en) 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
WO2014126836A1 (en) 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
WO2017044752A1 (en) 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
US11027021B2 (en) * 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US20190185471A1 (en) 2016-06-09 2019-06-20 Dr. Reddy's Laboratories Limited Solid forms of venetoclax and processes for the preparation of venetoclax
US20190225607A1 (en) 2016-07-06 2019-07-25 Concert Pharmaceuticals, Inc. Deuterated Venetoclax
CN107648185A (zh) 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
US20190177317A1 (en) 2016-08-12 2019-06-13 Mylan Laboratories Limited Process for the preparation of venetoclax
WO2018069941A2 (en) 2016-10-14 2018-04-19 Mylan Laboratories Limited Polymorphic forms of venetoclax
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
CZ201769A3 (cs) 2017-02-06 2018-08-15 Zentiva, K.S. Pevné formy venetoclaxu
WO2018157803A1 (zh) 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) * 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TW202038958A (zh) 2018-12-18 2020-11-01 比利時商阿根思公司 Ｃｄ７０組合治療

Also Published As

Publication number Publication date
UY38511A (es) 2020-07-31
EP4218761A1 (en) 2023-08-02
DK3890740T3 (da) 2023-05-08
SG11202105197UA (en) 2021-07-29
MX2021007350A (es) 2021-09-21
LT3890740T (lt) 2023-03-27
CN113226317A (zh) 2021-08-06
ES2941638T3 (es) 2023-05-24
FI3890740T3 (fi) 2023-05-24
PT3890740T (pt) 2023-05-15
CN115920034A (zh) 2023-04-07
IL284015A (en) 2021-08-31
WO2020127503A1 (en) 2020-06-25
AU2019409936A1 (en) 2021-05-27
TW202038958A (zh) 2020-11-01
JP2022515077A (ja) 2022-02-17
EP3890740B1 (en) 2023-03-01
US20240033353A1 (en) 2024-02-01
PL3890740T3 (pl) 2023-07-24
EP3890740A1 (en) 2021-10-13
HUE061710T2 (hu) 2023-08-28
KR20210106428A (ko) 2021-08-30
CN113226317B (zh) 2022-08-16
CA3117282A1 (en) 2020-06-25
US20200222532A1 (en) 2020-07-16
US11712468B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
CY1121813T1 (el) Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
EP4085919A3 (en) Compositions and methods to treat cancer
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
BR112018069976A2 (pt) anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo.
BR112022008817A2 (pt) Terapias combinadas para tratamento de câncer
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112022012885A2 (pt) Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.